Compare Illumina, Inc. (ILMN) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs JPMorgan Chase & Co — how do they compare? Illumina, Inc. trades at $189.79 (market cap $27.94B), while JPMorgan Chase & Co trades at $342.52 (market cap $900.78B). The key difference: JPMorgan Chase & Co is far larger — about 32.2× Illumina, Inc.'s market cap, and JPMorgan Chase & Co pays a 1.77% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | JPM | |
|---|---|---|
Market Cap | $27.94B | $900.78B |
Sector | Health | Financials |
52-Week High | $194.33 | $346.91 |
52-Week Low | $91.00 | $282.84 |
Enterprise Value | $29.33B | — |
Volume | — | 10,479,943 |
Dividend Yield | — | 1.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
JPMorgan Chase trades at $339.90, down 0.35% on the day, with strong technical momentum showing bullish moving averages and key support at $339. The company reported mixed Q4 2025 earnings but beat expectations in Q1 and Q2 2026, with revenue growing to $181.85 billion in 2025. Analyst consensus remains positive with a $372.73 price target, though CEO Jamie Dimon's recent warnings highlight economic risks.
JPMorgan presents a compelling investment case with solid fundamentals and Wall Street support, though investors face risks from macroeconomic volatility, cybersecurity threats, and geopolitical tensions. The stock's current valuation below analyst targets suggests potential upside if earnings momentum continues through upcoming quarterly results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
